Financial Highlights for the First Half of the Fiscal Year Ending March 31, 2025
Net sales increased by 1% year on year to 297,079 million yen. Operating profit was 2,876 million yen, up 0.3 % year on year. Ordinary profit was 3,637 million yen, up 4.6% year on year. The interim net profit attributable to owners of parent was 2,420 million yen, up 3.1% year on year. ・Achieved increases in both sales and profits in all the categories. Additionally, the progress made against all of our earnings forecasts exceeded 100%. ・Increase in revenue due to the increased sales of products eligible for the price maintenance premium in the pharmaceutical wholesaling business, our core business.